Singh Biotechnology (SBT) is a start-up biotech organization established in 2014 which discovers and develops unique and proprietary therapeutic single domain antibodies (sdAbs) for the treatment of a variety of cancers, autoimmune and ophthalmic diseases by leveraging its novel technology platform.